<DOC>
	<DOC>NCT00189722</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.</brief_summary>
	<brief_title>Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids &amp; Long Acting B2 Agonists in Moderate to Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Diagnosis of asthma Patients treated with inhaled corticosteroid and long acting beta 2 agonist FEV1(forced expiratory volume in 1 second)&gt;50% to 80% Respiratory infection within 2weeks Asthma exacerbation within 6 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppressant</keyword>
	<keyword>Anti-asthmatic drug</keyword>
	<keyword>Administration, inhalation</keyword>
</DOC>